24 results about "Receptorome" patented technology

The embodiment of the invention relates to the technical field of drug detection, in particular to an anti-CD38 antibody drug receptor occupation detection method and system, a peripheral blood sample is used for preparing a single-cell suspension, the single-cell suspension is divided into a TEST tube and an FMO tube, a cell surface antibody and an RO detection antibody are added into the TEST tube, only the cell surface antibody is added into the FMO tube, and only the RO detection antibody is added into the FMO tube. The TEST tube and the FMO tube are subjected to sample detection analysis, so that the average fluorescence intensity of RO detection antibodies of the TEST tube and the FMO tube is obtained. And performing RO detection analysis by adopting a dissociation method, taking the tubes which are not combined with the medicine as a total receptor group, taking the tubes which are combined with the medicine as a dissociation receptor group, and calculating an RO detection result according to the average fluorescence intensity of the TEST tube and the FMO tube.

Provided are compositions and method for prophylaxis and / or therapy of hearing loss or related dysfunctions, including but not limited to tinnitus, that could be ameliorated by restoring central nervous system inhibitory synapses. The compositions include polynucleotides and viral vectors that are used to express at least one GABA receptor component which may be a GABAA receptor alpha 1 subunit or GABAR receptor Ib subunit. Expression of the GABA receptor may be under control of a CaMKII promoter.

The present invention provides a chimeric antigen receptor (CAR) system comprising; (i) a receptor component comprising a antigen binding domain and a first binding domain; and (ii) a signalling component comprising a signalling domain and a second binding domain which binds the single domain binder of the first binding domain of the receptor component wherein either the first or second binding domains comprise a single domain binder, and wherein, binding of the first and second binding domains is disrupted by the presence of an agent, such that in the absence of the agent, the receptor component and the signalling component heterodimerize and binding of the antigen binding domain to antigen results in signalling through the signalling domain; whereas in the presence of the agent, the receptor component and the signalling component do not heterodimerize and binding of the antigen binding domain to antigen does not result in signalling through the signalling domain.

Disclosed are compositions comprising dominant negative chimeric tumor necrosis factor receptor 1 (TNFR1) fusion proteins and methods for use in cell therapies.

A method of treating a disease or disorder for which an increase in immune cells in the brain is therapeutic in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which specifically binds and increases activity of a receptor selected from the group consisting of a 5HT2C receptor, a 5HT2A receptor and a 5HT2B receptor in the postcentral gyrus and / or the choroid plexus (CP) of the brain of the subject. Compositions for treating these diseases are also disclosed.

Chimeric CD8 alpha co-receptor compositions and methods of use thereof are disclosed. In particular, chimeric CD8 [alpha] homodimer co-receptor compositions, cells comprising chimeric co-receptors, and pharmaceutical compositions comprising the co-receptors and / or cells are disclosed. Methods of making and using the co-receptor compositions are also provided.

Provided herein are multiplexed T cell receptor compositions, combination therapies, and uses thereof.

Provided herein are multiplexed T cell receptor compositions, combination therapies, and uses thereof.

Disclosed are compositions comprising dominant negative chimeric tumor necrosis factor receptor 1 (TNFR1) fusion proteins and methods for use in cell therapies.

The invention discloses a construction method of an ALS prognosis model based on chest CT skeletal muscle quantitative parameters. The method comprises the following steps: firstly, performing regular follow-up visit on an ALS receptor which is clearly diagnosed; imageJ software is used for quantifying skeletal muscle area / index / attenuation values (SMD / SMD / SMI) and paravertebral muscle area / attenuation values (PMA / PMD) of the first lumbar vertebra (L1) level of chest CT of all receptors and performing inter-group difference analysis, and it is found that the consistency of L1SMA / SMD / SMI / PMA / PMD of an ALS receptor group is reduced along with staging progress. According to the method, an ALS death risk prediction model is constructed through a single-factor and multi-factor COX proportional risk model, and a column diagram is drawn, so that L1SMA (HR is equal to 0.96, 95% CI is equal to 0.94-0.98, p is equal to 0.001), L1SMD (HR is equal to 0.92, 95% CI is equal to 0.88-0.96, plt; 0.001) and L1PMA (HR = 1.06, 95% CI = 1.01-1.11, plt; 0.022) significantly influences the survival rate of ALS, and areas under curves (AUC) of one-year survival prediction and three-year survival prediction are 0.687 and 0.851 respectively.

This invention relates to compositions and methods for modifying Cytokinin Receptor Histidine Kinase (HK) genes in plants, optionally to improve yield traits, the HK genes encoding a histidine kinase (HK) polypeptide. The invention further relates to plants having increased improved yield traits produced using the methods and compositions of the invention.

The application discloses a spoke-shaped decellularized cornea and a preparation method and application thereof, and belongs to the technical field of biomaterials and tissue engineering. The application realizes an orderly process of the phase change of water molecules along the temperature gradient direction by establishing a gradient temperature field from the periphery to the center of a sheet-shaped biological corneal tissue, and forms spoke-shaped microchannels in the cornea. The spoke-shaped microchannels can accelerate the decellularization process of the central region of the cornea, avoid excessive decellularization of the peripheral region of the cornea to cause excessive loss of bioactive components of the extracellular matrix, form a biomimetic migration path between the cornea and the receptor, facilitate the migration and infiltration of the cells of the receptor tissue into the cornea, promote the biological healing of the transplanted cornea and the limbus of the receptor cornea, and improve the biological stability of the transplanted cornea.

The application discloses a kind of biological sensors for detecting serum miRNA-21 of cervical cancer patient, it is related to the technical field of biosensor.The biological sensor of the application utilizes the large specific surface area of UiO-66-NH2, and Ru (bpy) 3 2+ Molecule (energy donor) and Ag nanoparticle (energy acceptor) are assembled in the same UiO-66-NH2, so that it exhibits high-efficiency intramolecular RET-ECL effect, enhances the ECL sensing response; Based on the stand point mediated strand displacement reaction and catalytic hairpin self-assembly signal amplification strategy, the diversity of substrate selection and the sensitivity of detection are improved; The catalysis of biological enzyme is used to improve the accuracy and timeliness of the biosensor. The biosensor of the application can be applied to the sensitive determination of miRNA-21 in the serum of cervical cancer patients, and has important application value.

Embodiments of the disclosure include methods and compositions for immunotherapy that comprise allogeneic cells that are able to be universally tolerated in host individuals. In specific embodiments the cells have reduced expression of endogenous beta2-microglobulin (B2M) and / or MHC class II-associated invariant chain (Ii), and in particular cases the cells are NKT cells that lack the ability to damage host tissues, have much reduced recognition by host immune cells, and surprisingly avoid destruction by host NK cells. In some embodiments, B2M- and / or Ii-targeting molecules are engineered to be expressed in combination (including within a single construct) with recombinantly engineered receptors, for example, for a one-hit generation of universally tolerated off-the-shelf immunotherapy.

This invention relates to compositions and methods for modifying Cytokinin Receptor Histidine Kinase (HK) genes in plants, optionally to improve yield traits, the HK genes encoding a histidine kinase (HK) polypeptide. The invention further relates to plants having increased improved yield traits produced using the methods and compositions of the invention.

The invention discloses a biosensor for detecting serum miRNA-21 of a cervical cancer patient, and relates to the technical field of biosensors. According to the biosensor disclosed by the invention, the Ru (bpy) 3 < 2 + > molecules (energy donors) and the Ag nanoparticles (energy receptors) are assembled in the same UiO-66-NH2 by utilizing the relatively large specific surface area of the UiO-66-NH2, so that the biosensor shows an efficient intramolecular RET-ECL effect, and the ECL sensing response is enhanced; based on a foothold mediated strand displacement reaction and a catalytic hairpin self-assembly signal amplification strategy, the diversity of substrate selection and the sensitivity of detection are improved; the accuracy and timeliness of the biosensor are improved by utilizing catalysis of the biological enzyme. The biosensor provided by the invention can be applied to sensitive determination of miRNA-21 in serum of cervical cancer patients, and has important application value.

The invention belongs to the technical field of biological medicines, and particularly relates to a universal anti-tumor SynNotch synthetic receptor combination, a Synn-MSC-BiTE / TriTE cell and an application of the SynNotch synthetic receptor combination and the Synn-MSC-BiTE / TriTE cell. According to the invention, BiTE / TriTE and MSC cells are integrated to obtain recombinant Syn-MSC-BiTE / TriTE cells, and a novel general tumor in-situ cell therapy, namely Syn-MSC-BiTE / TriTE, which takes MSC as a cell carrier and regulates BiTE / TriTE secretion mediating T cells through a SynNotch system to carry out tumor targeted killing is constructed. The receptor combination disclosed by the invention not only can be used for carrying out active permeation of solid tumors by utilizing the tumor chemotaxis of MSC, but also can be specifically and continuously expressed and accumulated in tumor tissues under the regulation and control of a SynNotch system, so that a powerful and long-acting tumor in-situ T cell anti-tumor reaction is mediated.

A method for differential drug discovery involves obtaining a set of receptors. The set of receptors specifies a plurality of targets and a plurality of anti-targets. The method also involves obtaining a small molecule compound (SMC) seed model and deriving a first plurality of candidate SMCs from the SMC seed model. For each of the candidate SMCs in the first plurality of candidate SMCs, a first desired interaction between the candidate SMC and each of the plurality of targets is simulated. Further, for each of the candidate SMCs in the first plurality of candidate SMCs, a first undesired interaction between the candidate SMC and each of the plurality of anti-targets is simulated. The method also involves obtaining, based on the first desired interactions and based on the first undesired interactions, a first SMC interaction score for each of the candidate SMCs in the first plurality of candidate SMCs; and determining, based on the first SMC interaction scores, whether at least a minimum fraction of drugs is reached.

A sensor device for an aerosol exposure system for in-vitro exposure of a cell culture to a test atmosphere is provided, the sensor device including: a measurement compartment configured to receive a receptor component of an electrochemical sensor for detecting one or more constituents of the test atmosphere; a receptor support arranged at an end of the measurement compartment and configured to support the receptor component of the electrochemical sensor; and a transducer component functionally couplable to the receptor component and configured to provide an electronically processable signal indicative of the one or more constituents in the test atmosphere.

Disclosed herein are methods of preventing and treating acute GVHD and chronic GVHD after hematopoietic cell transplantation (HCT), as well as methods of in vivo augmenting expansion of donor CD8+ T cells in the lymphoid tissues in vivo after HCT and methods of augmenting recipient tissue expression of programmed death-ligand 1 (PD-L1, or B7H1) after HCT. The methods entail administering one or more doses of an effective amount of a therapeutic agent to a recipient simultaneously, immediately before, or immediately after HCT to temporarily deplete CD4+ T cells or to reduce serum IL-2. Some examples include an anti-CD4 antibody or an anti-CD4-meditope-immunotoxin, an anti-IL-2 antibody, an agent blocking IL-2R, and / or a PD-L1-Ig. One or more additional therapeutic agents such as IFN-γ can be administered.

A programmable cell receptor complex expressed by an immunocyte, wherein the programmable receptor complex includes a plurality modified receptor subunits, wherein the modified receptor subunits have been engineered or modified to include FcγRI receptor components, biotin-binding components, or both, and wherein the FcγRI receptor components and biotin-binding components are operative to bind to target detector molecules that bind to or otherwise interact with predetermined targets.

The present application relates to PD-1 switch receptors, e.g., chimeric PD-1 switch receptors, in combination with a FAS dominant negative receptor, optionally in combination with a safety switch, e.g., truncated EGFR, which can be used in adoptive cell therapy to treat human diseases and disorders.

The present application relates to PD-1 switch receptors, e.g., chimeric PD-1 switch receptors, in combination with a FAS dominant negative receptor, optionally in combination with a safety switch, e.g., truncated EGFR, which can be used in adoptive cell therapy to treat human diseases and disorders.

A method for differential drug discovery involves obtaining a receptor panel which specifies a multitude of targets and a multitude of anti-targets. The method further involves obtaining a small molecule compound (SMC) seed model and derivatizing a first multitude of candidate SMCs from the SMC seed model. For each of the candidate SMCs in the first multitude of candidate SMCs, first desired interactions between the candidate SMC and each of the multitude of targets are simulated, and first undesired interactions between the candidate SMC and each of the multitude of anti-targets are simulated. The method also involves obtaining a first SMC interaction score for each of the candidate SMCs in the first multitude of candidate SMCs based on the first desired interactions and the first undesired interactions, and based on the first SMC interaction score, determining whether at least a minimum score for a drug is reached.